Pharming Group N.V annual capital expenditures (capex)
2019
2020
2021
2022
2023
2024
2025
Pharming Group N.V Capital Expenditures (CapEx) Growth & History (PHAR)
Pharming Group N.V's capital expenditures (capex) was $749,000 for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $749,000 | −$41,000 | −5.19% |
| 2024 | 2024-12-31 | $790,000 | −$647,000 | −45.02% |
| 2023 | 2023-12-31 | $1.4M | $61,000 | +4.43% |
| 2022 | 2022-12-31 | $1.4M | −$9.4M | −87.19% |
| 2021 | 2021-12-31 | $10.7M | $6.1M | +130.60% |
| 2020 | 2020-12-31 | $4.7M | $2.0M | +75.94% |
| 2019 | 2019-12-31 | $2.6M | — | — |
Pharming Group N.V quarterly capital expenditures (capex)
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $83,000 | −$45,000 | −35.16% |
| Q1 2026 | 2026-03-31 | $238,000 | — | — |
| Q4 2025 | 2025-12-31 | $269,000 | — | — |
| Q3 2025 | 2025-09-30 | $70,000 | — | — |
| Q2 2025 | 2025-06-30 | $128,000 | — | — |
Pharming Group N.V capital expenditures (capex) trends
Over the last five fiscal years, Pharming Group N.V's capital expenditures (capex) decreased from $4.7M to $749,000, a change of −$3.9M. The latest reported quarter, Q2 2026, shows $83,000.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...